Ignite Creation Date:
2025-12-24 @ 12:55 PM
Ignite Modification Date:
2026-01-07 @ 8:28 AM
Study NCT ID:
NCT05644561
Status:
RECRUITING
Last Update Posted:
2025-12-11
First Post:
2022-12-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Sponsor:
Alexion Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-24
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-01
First Submit QC Date:
None
Study First Post Date:
2022-12-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-05
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED